Risk factor
Very poor trading liquidity
Profitability factor
Very strong margins and returns
About
Operating under its OneMed brand, PT Jayamas Medica Industri Tbk specializes in the production and distribution of a diverse array of medical devices and supplies. The company's reach extends across Indonesia, Asia, the United States, South America, and Africa. Its business operations are structured into three primary segments: manufacturing, distribution, and retail. The extensive product portfolio includes a comprehensive selection of disposable and consumable medical items, such as syringes, gauze, plaster bandages, masks, medical gloves, urine bags, foley catheters, and alcoholic tissues. Additionally, it provides various antiseptic and disinfectant solutions, including povidone iodine, medical alcohol, and blood cleansing liquids like Hdsol. Diagnostic instruments and equipment form another key category, offering everything from patient monitors, vital signs monitors, and ECG readers to syringe pumps, infusion pumps, tensimeters, and oxymeters. For mobility and rehabilitation, the company supplies products like wheelchairs, crutches, and walkers. Its biotechnology and laboratory offerings encompass pregnancy tests, PCR tests, blood collection tubes, PCT tubes, and chemical reagents. Rounding out its inventory are hospital furnishings, such as patient beds, bedside cabinets, pediatric patient beds, and surgical lamps, alongside other general consumer medical products. These essential medical goods are distributed and retailed through the company's network of Medicom stores and various digital platforms. PT Jayamas Medica Industri Tbk was founded in Sidoarjo, Indonesia, in 2000 and functions as a subsidiary of Pt. Intisumber Hasilsempurna.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD
Target Price
The average target price of OMED.JK is 281 and suggests 28.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in